{
    "clinical_study": {
        "@rank": "40019", 
        "arm_group": [
            {
                "arm_group_label": "RH group", 
                "arm_group_type": "Experimental", 
                "description": "Radical hysterectomy followed by tailored adjuvant therapy"
            }, 
            {
                "arm_group_label": "CCRT group", 
                "arm_group_type": "Active Comparator", 
                "description": "Primary concurrent chemoradiation therapy"
            }
        ], 
        "brief_summary": {
            "textblock": "To compare 5-year overall survival between patients who undergo radical hysterectomy\n      followed by tailored adjuvant therapy and patients who receive primary chemoradiation\n      therapy in FIGO stage IB2 and IIA2 cervical cancer"
        }, 
        "brief_title": "Radical Hysterectomy Followed by Tailored Adjuvant Therapy Versus Primary Chemoradiation Therapy in Bulky Early-stage Cervical Cancer (KGOG 1029)", 
        "condition": "Cervical Cancer", 
        "condition_browse": {
            "mesh_term": "Uterine Cervical Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Previously untreated, histologically confirmed cervical cancer\n\n          -  FIGO stage IB2 and IIA2 disease\n\n          -  One of following histologic types\n\n               1. Squamous cell carcinoma\n\n               2. Adenocarcinoma\n\n               3. Adenosquamous carcinoma\n\n          -  Gynecologic Oncology Group performance status: 0-2\n\n          -  Adequate organ function\n\n               1. Bone marrow: WBC > 3000/mm3, ANC \u2265 1,000/mm3, Platelet \u2265 100*103/mm3, Hemoglobin\n                  \u2265 10g/dL\n\n               2. Kidney: Creatine < 1.25 * upper normal limit\n\n               3. Liver: AST, ANT < 3 * upper normal limit, Total bilirubin < 1.5 mg/mm3\n\n          -  Patient who have Singed an approved informed consent\n\n        Exclusion Criteria:\n\n          -  Patients with cervical cancer who have received any previous radiation or\n             chemotherapy\n\n          -  Neuroendocrine carcinoma of uterine cervix\n\n          -  Occult cervical cancer which was found after simple hysterectomy\n\n          -  Para-aortic nodal involvement (> 10 mm short axis diameter on pretreatment imaging\n             study)\n\n          -  History of other invasive malignancies, with the exception of non-melanoma skin\n             cancer, in situ melanoma and thyroid cancer, who had (or have) no evidence of the\n             other cancer present within the last 5 years\n\n          -  Serious illness or medical condition that precludes the safe administration of the\n             trial treatment including, but not limited to, ongoing or active infection,\n             symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia,\n             or psychiatric illness/social situations that would limit compliance with study\n             requirements\n\n          -  Prior diagnosis of Crohn's disease or ulcerative colitis\n\n          -  Neurologic or psychiatric disease\n\n          -  Patients who are pregnant or lactating"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "409", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 4, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01680523", 
            "org_study_id": "KGOG 1029"
        }, 
        "intervention": [
            {
                "arm_group_label": "RH group", 
                "description": "Piver-Rutledge type III hysterectomy New classification type C2 hysterectomy Open, vaginal, laparoscopic assisted, laparoscopic, robotic radical hysterectomy are all allowed", 
                "intervention_name": "Radical hysterectomy", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": "RH group", 
                "description": "After radical hysterectomy, intermediate risk group according to GOG protocol 92 criteria will receive adjuvant radiation therapy. High risk group will receive adjuvant chemoradiation therapy with weekly cisplatin (40mg/m2, IV for 6 cycles). Extended filed radiation therapy is allowed in case of common iliac lymph node or para-aortic lymph node metastasis. Intracavitary brachytherapy and nodal or parametrial boost is not allowed.", 
                "intervention_name": "Tailored adjuvant therapy", 
                "intervention_type": "Radiation", 
                "other_name": [
                    "Adjuvant radiation therapy", 
                    "Adjuvant chemoradiation therapy"
                ]
            }, 
            {
                "arm_group_label": "CCRT group", 
                "description": "Patient will receive primary radiation therapy including external pelvic irradiation, intracavitary brachytherapy, and parametrial or nodal boost. Extended filed radiation therapy is allowed in case of common iliac lymph node enlargement. Patients will receive concurrent weekly cisplatin (cisplatin 40mg/m2 for 6 cycles) during external radiation therapy.", 
                "intervention_name": "Primary chemoradiation therapy", 
                "intervention_type": "Radiation"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "cervical cancer", 
            "bulky early-stage", 
            "locally advanced", 
            "radical hysterectomy", 
            "concurrent chemoradiation therapy"
        ], 
        "lastchanged_date": "September 8, 2012", 
        "location": {
            "contact": {
                "email": "jhnam@amc.seoul.kr", 
                "last_name": "Joo-Hyun Nam, M.D., Ph.D.", 
                "phone": "82-2-3010-3633"
            }, 
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of", 
                    "zip": "138-736"
                }, 
                "name": "Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized Controlled Trial Comparing Radical Hysterectomy Plus Tailored Adjuvant Therapy Versus Primary Chemoradiation Therapy in Bulky Early-stage Cervical Cancer (KGOG 1029)", 
        "overall_contact": {
            "email": "jhnam@amc.seoul.kr", 
            "last_name": "Joo-Hyun Nam, M.D., Ph.D.", 
            "phone": "82-2-3010-3633"
        }, 
        "overall_official": {
            "affiliation": "Asan Medical Center", 
            "last_name": "Joo-Hyun Nam, M.D., Ph.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Asan Medical Center Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "July 2020", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "5-year overall survival", 
            "safety_issue": "No", 
            "time_frame": "5 year after treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01680523"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Asan Medical Center", 
            "investigator_full_name": "Joo-Hyun Nam", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "5-year progression-free survival", 
                "safety_issue": "No", 
                "time_frame": "5 years after treatment"
            }, 
            {
                "measure": "Pattern of disease recurrence", 
                "safety_issue": "No", 
                "time_frame": "within 5 years afer treatment"
            }, 
            {
                "description": "Treatment related toxicity will be evaluated using CTCAE v3.0.", 
                "measure": "Treatment-related toxicity", 
                "safety_issue": "Yes", 
                "time_frame": "within 5 years after treatment"
            }, 
            {
                "measure": "Quality of life", 
                "safety_issue": "No", 
                "time_frame": "within 1 year after treatment"
            }
        ], 
        "source": "Asan Medical Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Asan Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2012"
    }
}